An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice

Clinical and Vaccine Immunology

Volumn 20, Issue 7, 2013, Pages 998-1007

  Haredy, Ahmad M ^a,d   Takenaka, Nobuyuki ^a   Yamada, Hiroshi ^a   Sakoda, Yoshihiro ^b   Okamatsu, Masatoshi ^b   Yamamoto, Naoki ^b   Omasa, Takeshi ^d,e   Ohtake, Hisao ^d   Mori, Yasuko ^a,f   Kida, Hiroshi ^b,c   Yamanishi, Koichi ^a   Okamoto, Shigefumi ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

^f KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; INFLUENZA VACCINE; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFECT; FEMALE; GENETIC CODE; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MDCK CELL; MOLECULAR LIBRARY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PA GENE; PB2 GENE; POINT MUTATION; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRAL CLEARANCE; VIRION; VIRUS GENE; VIRUS INACTIVATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TITRATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS PROTECTION; DOGS; FEMALE; FORMALDEHYDE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LEUKOCYTES, MONONUCLEAR; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; REASSORTANT VIRUSES; VACCINES, INACTIVATED; VIRUS INACTIVATION;

EID: 84880451684     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00024-13     Document Type: Article

References (47)

1. Doherty PC, Turner SJ, Webby RG, Thomas PG. 2006. Influenza and the challenge for immunology. Nat. Immunol. 7:449-455.
2. Russell CJ, Webster RG. 2005. The genesis of a pandemic influenza virus. Cell 123:368-371. (Pubitemid 41546667)
3. Wright PF, Neuman G, Kawaoka Y. 2007. Orthomyxoviruses, p 1691-1740. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
4. Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine 21:1776-1779. (Pubitemid 36398372)
5. Isoda N, Sakoda Y, Kishida N, Soda K, Sakabe S, Sakamoto R, Imamura T, Sakaguchi M, Sasaki T, Kokumai N, Ohgitani T, Saijo K, Sawata A, Hagiwara J, Lin Z, Kida H. 2008. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia. Arch. Virol. 153:1685-1692.
6. Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R, Sakoda Y, Kawaoka Y, Ogasawara K, Kida H. 2008. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine 26:562-572.
7. Kida H, Sakoda Y. 2006. Library of influenza virus strains for vaccine and diagnostic use against highly pathogenic avian influenza and human pandemics. Dev. Biol. (Basel) 124:69-72. (Pubitemid 43258901)
8. Samad RA, Nomura N, Tsuda Y, Manzoor R, Kajihara M, Tomabechi D, Sasaki T, Kokumai N, Ohgitani T, Okamatsu M, Takada A, Sakoda Y, Kida H. 2011. A vaccine prepared from a non-pathogenic H5N1 influenza virus strain from the influenza virus library conferred protective immunity to chickens against the challenge with antigenically drifted highly pathogenic avian influenza virus. Jpn. J. Vet. Res. 59:23-29.
9. Soda K, Ozaki H, Sakoda Y, Isoda N, Haraguchi Y, Sakabe S, Kuboki N, Kishida N, Takada A, Kida H. 2008. Antigenic and genetic analysis of H5 influenza viruses isolated from water birds for the purpose of vaccine use. Arch. Virol. 153:2041-2048.
10. Soda K, Sakoda Y, Isoda N, Kajihara M, Haraguchi Y, Shibuya H, Yoshida H, Sasaki T, Sakamoto R, Saijo K, Hagiwara J, Kida H. 2008. Development of vaccine strains of H5 and H7 influenza viruses. Jpn. J. Vet. Res. 55:93-98. (Pubitemid 351325956)
11. Murakami S, Horimoto T, Ito M, Takano R, Katsura H, Shimojima M, Kawaoka Y. 2012. Enhanced growth of influenza vaccine seed viruses in Vero cells mediated by broadening the optimal pH range for virus membrane fusion. J. Virol. 86:1405-1410.
12. Genzel Y, Behrendt I, Konig S, Sann H, Reichl U. 2004. Metabolism of MDCK cells during cell growth and influenza virus production in largescale microcarrier culture. Vaccine 22:2202-2208. (Pubitemid 38626059)
13. Hu AY, Tseng YF, Weng TC, Liao CC, Wu J, Chou AH, Chao HJ, Gu A, Chen J, Lin SC, Hsiao CH, Wu SC, Chong P. 2011. Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS One 6:e14578. doi:10.1371/journal.pone.0014578.
14. Hu AY, Weng TC, Tseng YF, Chen YS, Wu CH, Hsiao S, Chou AH, Chao HJ, Gu A, Wu SC, Chong P, Lee MS. 2008. Microcarrier-based MDCKcell culture system for the production of influenza H5N1 vaccines. Vaccine 26:5736-5740.
15. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. 1998. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16:960-968. (Pubitemid 28276008)
16. Bernstein DI. 2010. Cell culture-derived influenza vaccines: has their time come? Clin. Infect. Dis. 51:1005-1006.
17. Onions D, Egan W, Jarrett R, Novicki D, Gregersen JP. 2010. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 38:544-551.
18. Hussain AI, Cordeiro M, Sevilla E, Liu J. 2010. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semipermissive cells. Vaccine 28:3848-3855.
19. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H. 2005. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79:2910-2919. (Pubitemid 40270569)
20. Mizuno D, Ide-Kurihara M, Ichinomiya T, Kubo I, Kido H. 2006. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. J. Immunol. 176:1122-1130. (Pubitemid 43099714)
21. Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto T, Ishikawa T, Takahashi M, Yamanishi K, Mori Y. 2009. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Vaccine 27: 5896-5905.
22. Tamura S, Hasegawa H, Kurata T. 2010. Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn. J. Infect. Dis. 63:8-15.
23. Tamura SI, Samegai Y, Kurata H, Kikuta K, Nagamine T, Aizawa C, Kurata T. 1989. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine 7:257-262. (Pubitemid 19174464)
24. Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, Ishikawa T, Akagi T, Akashi M, Okuno Y, Mori Y, Yamanishi K. 2012. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin. Vaccine Immunol. 19:979-990.
25. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. 2003. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21:3212-3218. (Pubitemid 36700428)
26. Yamada H, Moriishi E, Haredy AM, Takenaka N, Mori Y, Yamanishi K, Okamoto S. 2012. Influenza virus neuraminidase contributes to the dextran sulfate-dependent suppressive replication of some influenza A virus strains. Antiviral Res. 96:344-352.
27. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. 2001. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 146:2275-2289. (Pubitemid 34682391)
28. Okamoto S, Yoshii H, Akagi T, Akashi M, Ishikawa T, Okuno Y, Takahashi M, Yamanishi K, Mori Y. 2007. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Vaccine 25:8270-8278. (Pubitemid 350087384)
29. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12:1203-1207. (Pubitemid 44527358)
30. Thanh TT, van Doorn HR, de Jong MD. 2008. Human H5N1 influenza: current insight into pathogenesis. Int. J. Biochem. Cell Biol. 40:2671-2674.
31. James JM, Zeiger RS, Lester MR, Fasano MB, Gern JE, Mansfield LE, Schwartz HJ, Sampson HA, Windom HH, Machtinger SB, Lensing S. 1998. Safe administration of influenza vaccine to patients with egg allergy. J. Pediatr. 133:624-628. (Pubitemid 28521210)
32. Katz JM, Webster RG. 1992. Amino acid sequence identity between the HA1 of influenza A (H3N2) viruses grown in mammalian and primary chick kidney cells. J. Gen. Virol. 73:1159-1165.
33. Minor PD. 2010. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin. Infect. Dis. 50:560-565.
34. Minor PD, Engelhardt OG, Wood JM, Robertson JS, Blayer S, Colegate T, Fabry L, Heldens JG, Kino Y, Kistner O, Kompier R, Makizumi K, Medema J, Mimori S, Ryan D, Schwartz R, Smith JS, Sugawara K, Trusheim H, Tsai TF, Krause R. 2009. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 27:2907-2913.
35. Organ WH. 1995. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull. World Health Organ. 73:431-435.
36. Neumann G, Kawaoka Y. 2006. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg. Infect. Dis. 12:881-886. (Pubitemid 43848407)
37. Bogs J, Kalthoff D, Veits J, Pavlova S, Schwemmle M, Manz B, Mettenleiter TC, Stech J. 2011. Reversion of PB2-627E to -627K during replication of an H5N1 clade 2.2 virus in mammalian hosts depends on the origin of the nucleoprotein. J. Virol. 85:10691-10698.
38. Hatta M, Gao P, Halfmann P, Kawaoka Y. 2001. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293:1840-1842. (Pubitemid 32845783)
39. Li Y, Shi J, Zhong G, Deng G, Tian G, Ge J, Zeng X, Song J, Zhao D, Liu L, Jiang Y, Guan Y, Bu Z, Chen H. 2010. Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009. J. Virol. 84:8389-8397.
40. Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, Szretter KJ, Chen LM, Thawatsupha P, Chittaganpitch M, Waicharoen S, Nguyen DT, Nguyen T, Nguyen HH, Kim JH, Hoang LT, Kang C, Phuong LS, Lim W, Zaki S, Donis RO, Cox NJ, Katz JM, Tumpey TM. 2005. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J. Virol. 79:11788 - 11800.
41. Murakami S, Horimoto T, Mai le Q, Nidom CA, Chen H, Muramoto Y, Yamada S, Iwasa A, Iwatsuki-Horimoto K, Shimojima M, Iwata A, Kawaoka Y. 2008. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. J. Virol. 82:10502-10509. (Pubitemid 352691163)
42. Schat KA, Bingham J, Butler JM, Chen LM, Lowther S, Crowley TM, Moore RJ, Donis RO, Lowenthal JW. 2012. Role of position 627 of PB2 and the multibasic cleavage site of the hemagglutinin in the virulence of H5N1 avian influenza virus in chickens and ducks. PLoS One 7:e30960. doi:10.1371/journal.pone. 0030960.
43. Kashima Y, Ikeda M, Itoh Y, Sakoda Y, Nagata T, Miyake T, Soda K, Ozaki H, Nakayama M, Shibuya H, Okamatsu M, Ishigaki H, Ishida H, Sawai T, Kawaoka Y, Kida H, Ogasawara K. 2009. Intranasal administration of a live non-pathogenic avian H5N1 influenza virus from a virus library confers protective immunity against H5N1 highly pathogenic avian influenza virus infection in mice: comparison of formulations and administration routes of vaccines. Vaccine 27:7402-7408.
44. Furuya Y, Chan J, Regner M, Lobigs M, Koskinen A, Kok T, Manavis J, Li P, Mullbacher A, Alsharifi M. 2010. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by γ-irradiated influenza A viruses. J. Virol. 84:4212-4221.
45. Furuya Y, Regner M, Lobigs M, Koskinen A, Mullbacher A, Alsharifi M. 2010. Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations. J. Gen. Virol. 91:1450-1460.
46. Sawai T, Itoh Y, Ozaki H, Isoda N, Okamoto K, Kashima Y, Kawaoka Y, Takeuchi Y, Kida H, Ogasawara K. 2008. Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin. Immunology 124:155-165. (Pubitemid 351692896)
47. Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, Wilschut J, de Haan A. 2012. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS One 7:e30898. doi:10.1371/journal.pone.0030898. Diseases